Tc Biopharm Plc Stock Return On Equity
| TCBPW Stock | USD 0.01 0 6.25% |
TC BioPharm plc fundamentals help investors to digest information that contributes to TC BioPharm's financial success or failures. It also enables traders to predict the movement of TCBPW Stock. The fundamental analysis module provides a way to measure TC BioPharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TC BioPharm stock.
| Last Reported | Projected for Next Year | ||
| Return On Equity | (2.20) | (2.09) |
TCBPW | Return On Equity |
TC BioPharm plc Company Return On Equity Analysis
TC BioPharm's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current TC BioPharm Return On Equity | -12.17 |
Most of TC BioPharm's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TC BioPharm plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
TCBPW Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for TC BioPharm is extremely important. It helps to project a fair market value of TCBPW Stock properly, considering its historical fundamentals such as Return On Equity. Since TC BioPharm's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of TC BioPharm's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of TC BioPharm's interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
TCBPW Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, TC BioPharm plc has a Return On Equity of -12.1748. This is 49.21% lower than that of the Biotechnology sector and 66.61% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
TCBPW Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TC BioPharm's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TC BioPharm could also be used in its relative valuation, which is a method of valuing TC BioPharm by comparing valuation metrics of similar companies.TC BioPharm is currently under evaluation in return on equity category among its peers.
TCBPW Fundamentals
| Return On Equity | -12.17 | ||||
| Return On Asset | -1.09 | ||||
| Number Of Shares Shorted | 529 | ||||
| EBITDA | (13.61 M) | ||||
| Net Income | (5.91 M) | ||||
| Cash And Equivalents | 1.55 M | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.8 M | ||||
| Current Ratio | 0.18 X | ||||
| Book Value Per Share | 3.38 X | ||||
| Cash Flow From Operations | (10.54 M) | ||||
| Earnings Per Share | (0.75) X | ||||
| Number Of Employees | 41 | ||||
| Beta | 0.25 | ||||
| Total Asset | 8.93 M | ||||
| Retained Earnings | (38.84 M) | ||||
| Working Capital | 950.33 K | ||||
| Net Asset | 8.93 M |
About TC BioPharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TC BioPharm plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TC BioPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TC BioPharm plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for TCBPW Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.